Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

An in vitro study to assess facial and ocular deposition from Respimat Soft Mist inhaler.

Newman SP, Steed KP, Reader SJ, Pavia D, Sohal AK.

J Aerosol Med. 2007 Spring;20(1):7-12.

PMID:
17388748
3.

Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.

Hochrainer D, Hölz H, Kreher C, Scaffidi L, Spallek M, Wachtel H.

J Aerosol Med. 2005 Fall;18(3):273-82.

PMID:
16181002
4.

Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.

Brand P, Hederer B, Austen G, Dewberry H, Meyer T.

Int J Chron Obstruct Pulmon Dis. 2008;3(4):763-70.

6.

Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler.

Hodder R, Pavia D, Dewberry H, Alexander K, Iacono P, Ponitz H, Beck E.

Respir Med. 2005 Sep;99(9):1087-95.

7.

Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD.

Kilfeather SA, Ponitz HH, Beck E, Schmidt P, Lee A, Bowen I, Hesse Ch.

Respir Med. 2004 May;98(5):387-97.

PMID:
15139567
8.

The Respimat Soft Mist Inhaler, a Novel Inhaled Drug Delivery Device.

Perriello EA, Sobieraj DM.

Conn Med. 2016 Jun-Jul;80(6):359-64. Review.

PMID:
27509644
9.
11.

Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction.

Schürmann W, Schmidtmann S, Moroni P, Massey D, Qidan M.

Treat Respir Med. 2005;4(1):53-61.

PMID:
15725050
12.

Inhaled ethanolic and aqueous solutions via Respimat Soft Mist Inhaler are well-tolerated in asthma patients.

Patel KR, Pavia D, Lowe L, Spiteri M.

Respiration. 2006;73(4):434-40. Epub 2005 Oct 30.

PMID:
16484767
13.

A review of the development of Respimat Soft Mist Inhaler.

Dalby R, Spallek M, Voshaar T.

Int J Pharm. 2004 Sep 28;283(1-2):1-9. Review.

PMID:
15363496
14.

Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler.

Pavia D, Moonen D.

J Aerosol Med. 1999;12 Suppl 1:S33-9. Review.

PMID:
10623340
15.

Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma.

von Berg A, Jeena PM, Soemantri PA, Vertruyen A, Schmidt P, Gerken F, Razzouk H.

Pediatr Pulmonol. 2004 Mar;37(3):264-72.

PMID:
14966821
16.

Asthma patients prefer Respimat Soft Mist Inhaler to Turbuhaler.

Hodder R, Reese PR, Slaton T.

Int J Chron Obstruct Pulmon Dis. 2009;4:225-32. Epub 2009 Jun 11.

17.

The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.

van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C.

Respir Med. 2009 Jan;103(1):22-9. doi: 10.1016/j.rmed.2008.10.002. Epub 2008 Nov 20.

18.

Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach.

Worth Longest P, Hindle M.

J Aerosol Med Pulm Drug Deliv. 2009 Jun;22(2):99-112. doi: 10.1089/jamp.2008.0708.

PMID:
18956950
19.

Patient preferences for inhaler devices in chronic obstructive pulmonary disease: experience with Respimat Soft Mist inhaler.

Hodder R, Price D.

Int J Chron Obstruct Pulmon Dis. 2009;4:381-90. Epub 2009 Oct 19. Review.

20.

Use of Respimat Soft Mist inhaler in COPD patients.

Anderson P.

Int J Chron Obstruct Pulmon Dis. 2006;1(3):251-9. Review.

Supplemental Content

Support Center